| Literature DB >> 30177651 |
Wen-Cong Yang1, Hai-Yan Bao2,3, Ya-Yue Liu4, Ying-Ying Nie5,6, Jing-Ming Yang7, Peng-Zhi Hong8,9, Yi Zhang10,11.
Abstract
A new depsidone derivative (1), aspergillusidone G, was isolated from a marine fungus Aspergillus unguis, together with eight known depsidones (2‒9) and a cyclic peptide (10): agonodepside A (2), nornidulin (3), nidulin (4), aspergillusidone F (5), unguinol (6), aspergillusidone C (7), 2-chlorounguinol (8), aspergillusidone A (9), and unguisin A (10). Compounds 1‒4 and 7‒9 were obtained from the plasma induced mutant of this fungus, while 5, 6, and 10 were isolated from the original strain under chemical induction. Their structures were identified using spectroscopic analysis, as well as by comparison with literature data. The HPLC fingerprint analysis indicates that chemical induction and plasma mutagenesis effectively influenced the secondary metabolism, which may be due to their regulation in the key steps in depsidone biosynthesis. In bioassays, compound 9 inhibited acetylcholinesterase (AChE) with IC50 in 56.75 μM. Compounds 1, 5, 7, 8, and 9 showed moderate to strong activity towards different microbes. Compounds 3, 4, and 5 exhibited potent larvicidality against brine shrimp. In docking studies, higher negative CDOCKER interaction energy and richer strong interactions between AChE and 9 explained the greater activity of 9 compared to 1. Chemical induction and plasma mutagenesis can be used as tools to expand the chemodiversity of fungi and obtain useful natural products.Entities:
Keywords: Aspergillus unguis; chemical induction; depsidones; docking; plasma-induced mutant
Mesh:
Substances:
Year: 2018 PMID: 30177651 PMCID: PMC6225302 DOI: 10.3390/molecules23092245
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Structures of compounds 1‒10.
NMR data for 1 measured in CD3OD.
| Position | Position | ||||
|---|---|---|---|---|---|
| 1 | 104.5, C | 3′ | 116.9, C | ||
| 2 | 144.7, C | 4′ | 161.8, C | ||
| 3 | 113.5, CH | 6.28, dd, (2.0, 0.5) | 5′ | 114.3, CH | 6.25, s |
| 4 | 166.9, C | 6′ | 148.7, C | ||
| 5 | 102.2, CH | 6.19, d, (2.4) | 7′ | 141.1, C | |
| 6 | 165.9, C | 8′ | 120.6, CH | 5.34, dq, (6.8, 1.3) | |
| 7 | 171.3, C | 9′ | 14.0, CH3 | 1.70, dd, (6.8, 0.8) | |
| 8 | 24.6, CH3 | 2.59, s | 10′ | 18.8, CH3 | 1.92, s |
| 1′ | 116.7, C | 11′ | 9.6, CH3 | 2.01, s | |
| 2′ | 151.3, C | 12′ | 175.2, C |
a 13C-NMR recorded in CD3OD at 125 MHz; b 1H-NMR recorded in CD3OD at 500 MHz.
Figure 2Key COSY (bold line) and HMBC (arrow) correlations of compound 1.
Figure 3The HPLC fingerprints recorded at 254 nm of Aspergillus unguis fermentation extracts when cultured under different conditions. (A) A. unguis in potato sucrose broth (PSB) medium; (B) A. unguis in PSB medium + NaBr; (C) A. unguis in PSB medium + procaine; (D) A. unguis in PSB medium + procaine + NaBr; (E) A. unguis treat with plasma in PSB medium.
Figure 4Probable proposed biosynthetic pathways for depsides 1‒2 and depsidones 3‒9, KS, ketosynthase; AT, acytransferase; ACP, acyl carrier protein; SAM, S-Adenosyl methionione [19,26,27,28].
Antimicrobial activities of compounds 1‒10, measured using the paper disk method.
| Strains | Zone of Inhibition (mm) # | ||||
|---|---|---|---|---|---|
| Compounds |
| MRSA |
| ||
|
| 7.7 ± 0.6 | 12.0 ± 1.0 | 9.3 ± 0.6 | 8.3 ± 0.6 | |
|
| - | - | 8.0 ± 0.0 | 6.0 ± 0.5 | |
|
| 12.2 ± 0.3 | - | - | 12.1 ± 0.2 | |
|
| 9.5 ± 0.6 | 9.0 ± 0.0 | - | 9.0 ± 0.0 | |
|
| 11.9 ± 0.2 | 14.5 ± 0.6 | 6.3 ± 0.6 | 7.5 ± 0.6 | |
|
| 8.7 ± 2.1 | 7.0 ± 0.0 | 7.0 ± 0.0 | 8.0 ± 0.5 | |
|
| 10.0 ± 0.0 | 13.7 ± 2.3 | 9.7 ± 0.6 | 7.9 ± 0.2 | |
|
| 11.1 ± 0.2 | 17.0 ± 0.0 | 8.3 ± 0.6 | 10.0 ± 0.0 | |
|
| 16.0 ± 0.0 | 17.7 ± 0.6 | 8.3 ± 0.6 | 15.5 ± 2.2 | |
|
| - | - | 9.0 ± 0.0 | 6.0 ± 0.5 | |
| Ampicillin | 12.0 ± 1.4 | 14.0 ± 0.0 | 9.0 ± 0.0 | - | |
| Ketoconazole | - | - | - | 22.0 ± 0.0 | |
#: mean ± SD of three replicates; -: no or very weak activity; *: incomplete inhibition.
Antimicrobial activities of compounds 1‒10 tested by microdilution method.
| Strains | MIC (μM) | ||||
|---|---|---|---|---|---|
| Compounds |
| MRSA |
|
| |
|
| 102.4 | 51.2 | >102.4 | 12.8 | |
|
| - | - | >102.4 | - | |
|
| >102.4 | - | - | >102.4 | |
|
| >102.4 | 102.4 | - | >102.4 | |
|
| 6.4 | 25.6 | >102.4 | >102.4 | |
|
| 102.4 | >102.4 | >102.4 | >102.4 | |
|
| 25.6 | >102.4 | >102.4 | >102.4 | |
|
| 51.2 | 25.6 | >102.4 | >102.4 | |
|
| 102.4 | 12.8 | >102.4 | 6.4 | |
|
| - | - | >102.4 | - | |
| Ampicillin | 1.6 | 6.4 | 102.4 | - | |
| Ketoconazole | - | - | - | 1.9 | |
-: not tested.
AChE inhibitory activity, DPPH free radical scavenging activity, and larvicidality assay of compounds 1‒10.
| Compounds | AChE Inhibitory Activity | DPPH Scavenging Activity | Larvicidal Activity |
|---|---|---|---|
|
| >102.4 | >102.4 | >102.4 |
|
| >102.4 | >102.4 | >102.4 |
|
| >102.4 | >102.4 | 12.8 |
|
| >102.4 | >102.4 | 4.5 |
|
| >102.4 | >102.4 | 12.8 |
|
| >102.4 | >102.4 | >102.4 |
|
| >102.4 | >102.4 | 72 |
|
| >102.4 | >102.4 | 75.9 |
|
| 56.8 | >102.4 | 51.2 |
|
| >102.4 | >102.4 | >102.4 |
| Donepezil | 0.3 | - | - |
| Vitamin C | - | 31.8 | - |
| Hg(NO3)2 | - | - | 77.0 |
-: not tested.
Figure 5Representation of the binding mode of compounds 1 (A,C) and 9 (B,D) in the active site of AChE.